TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06708520
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 10 mg tablets
Study: NCT05508009
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
Study: NCT05508009
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
Study: NCT05508009
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
Study: NCT05508009
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
Study: NCT06329947
Drug: Surufatinib 250mg/d qd once daily
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
Study: NCT05827055
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
Study: NCT05827055
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
Study: NCT05827055
Drug: Proglumide
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
Study: NCT05008536
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study: NCT05008536
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study: NCT04795661
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenous (IV)
Study: NCT05502783
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin \< 10 g/dL, platelets \< 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
Study: NCT05499390
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive AK112 intravenously.
Study: NCT05499390
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive Pembrolizumab intravenously.
Study: NCT05266430
Drug: AU-011
Normalized name: Light-activated au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously received
Study: NCT05134792
Drug: intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
Study: NCT05815056
Drug: drug intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using sufentanyl 5mg intravenously during the surgery
Study: NCT05652686
Drug: Peluntamig (PT217)
Normalized name: PT217
DrugBank: PT217 (DB18472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bispecific antibody (bsAb) against DLL3 and CD47.
Study: NCT05652686
Drug: Carboplatin + Etoposide
Normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered per Standard of Care.
Study: NCT05652686
Drug: Paclitaxel.
DrugBank: Paclitaxel docosahexaenoic acid (DB05297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per Standard of Care.
Study: NCT05652686
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered per Standard of Care.
Study: NCT05687890
Drug: SC0062 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study: NCT05097326
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 200mg taken orally
Study: NCT05097326
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed
Study: NCT05489744
Drug: [14C]Afuresertib
DrugBank: Afuresertib (DB11648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
Study: NCT05399732
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
Study: NCT05687890
Drug: SC0062 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study: NCT06136403
Drug: deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment by deucravacitinib in two phases of challenge
Study: NCT06487559
Drug: Livmoniplimab
Normalized name: Livmoniplimab
DrugBank: Livmoniplimab (DB18939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06487559
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01865630
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
Study: NCT04946396
Drug: dexmedetomidine intravenous infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
Study: NCT04946396
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
Study: NCT06404905
Drug: BT02 monoclonal antibody injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is expected to include 10-30 patients assigned to dose escalation cohorts.
Study: NCT06298383
Drug: Trypsin, Bromelain and Rutoside
DrugBank: Trypsin (DB11237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.
Study: NCT04978649
Drug: Allisartan Isoproxil
Normalized name: Allisartan isoproxil
DrugBank: Allisartan isoproxil (DB18880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
Study: NCT04978649
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
Study: NCT06236672
Drug: basal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: basal insulin initiated between January 2019 and December 2022
Study: NCT04925167
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
Study: NCT04925167
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
Study: NCT02393482
Drug: Add back therapy 1 (tibolone)
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tibolone 5 mg/die
Study: NCT02393482
Drug: Add back therapy 2 (calcium carbonate/colecalciferol)
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium carbonate/colecalciferol (500mg/400UI)/die
Study: NCT05229913
Drug: Esketamine is not added
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
Study: NCT05327699
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
Study: NCT05552001
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
Study: NCT00000941
Drug: Atorvastatin calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000941
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000941
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000941
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000180
Drug: AIT-082
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05229913
Drug: Esketamine 0.2mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study: NCT05229913
Drug: Esketamine 0.4mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
Study: NCT05229913
Drug: Esketamine 0.6mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study: NCT05229913
Drug: Esketamine 0.8mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study: NCT04665648
Drug: Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
Study: NCT05136755
Drug: NMDAE
Normalized name: NMDA
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
Study: NCT04925986
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).
Study: NCT04925986
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
Study: NCT06209008
Drug: Intravesical injection of Platlet Rich Plasma (PRP)
Normalized name: plasma protein fraction Injection
DrugBank: Plasma protein fraction (human) (DB13968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
Study: NCT05495620
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous~carfilzomib, lenalidomide, dexamethasone
Study: NCT05495620
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT05495620
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral or intravenous
Study: NCT05232032
Drug: Nociceptin Receptor Antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
Study: NCT05328804
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05328804
Drug: Herombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally by mouth
Study: NCT04942899
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
Study: NCT05425914
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment option for dry eye patients with low serum vitamin D Level
Study: NCT05425914
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dry eye treatment
Study: NCT05399641
Drug: Ibrexafungerp
Normalized name: Ibrexafungerp
DrugBank: Ibrexafungerp (DB12471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each day dosing will consist of two 150mg tablets taken BID.
Study: NCT05658549
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl cysteine dosage 600 mg and 1200 mg
Study: NCT06091085
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
Study: NCT05494567
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
Study: NCT05494567
Drug: Tamsulosin Hcl 0.4 mg
Normalized name: tamsulosin HCl 0.4 mg ORAL CAPSULE
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
Study: NCT05494567
Drug: solifenacin 10 mg
Normalized name: solifenacin 10 mg oral tablet
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
Study: NCT05586009
Drug: cisplatin with hydration magnesium
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
Study: NCT05577845
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ramosetron, 4 weeks
Study: NCT05453383
Drug: Anlotinib;Toripalimab
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib Hydrochloride;Toripalimab injiection
Study: NCT05131984
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
Study: NCT06009705
Drug: toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
Study: NCT06099093
Drug: 18F-DCFPyl
Normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorine-labeled small molecule, via intravenous infusion per protocol.
Study: NCT06778967
Drug: GZR18
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06778967
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT05267366
Drug: PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
Study: NCT06040099
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab IV (intravenous)
Study: NCT06040099
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab IV (intravenous)
Study: NCT00002132
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002132
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05345509
Drug: Aricept Tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil Tablet once daily P.O
Study: NCT00002361
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002361
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06547489
Drug: Zelquistinel
Normalized name: Zelquistinel
DrugBank: Zelquistinel (DB19336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Study: NCT05709288
Drug: BBM-H901
Normalized name: BBM-H901
DrugBank: BBM-H901 (DB17704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
Study: NCT04533490
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
Study: NCT05024799
Drug: Butorphanol and propofol
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in this group will be administered with butorphanol and propofol
Study: NCT05024799
Drug: Butorphanol and dexmedetomindine
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in this group will be administered with butorphanol and dexmedetomindine
Study: NCT04858711
Drug: ketamine-lidocaine-dexmedetomidine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.